Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial

STUDY QUESTION: Are progesterone vaginal pessaries 400 mg twice a day (bid) non-inferior to progesterone vaginal gel (90 mg) once a day (od) in the primary endpoint of clinical pregnancy rate after 38 days of luteal phase support in women undergoing in vitro fertilisation (IVF)? SUMMARY ANSWER: Non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, Helen, Khan, Cass, D’Hooghe, Thomas, Magnúsdóttir, Thora Björg, Klingmann, Ingrid, Hrafnsdóttir, Sigrún
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048710/
https://www.ncbi.nlm.nih.gov/pubmed/32074281
http://dx.doi.org/10.1093/humrep/dez261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048710/
https://www.ncbi.nlm.nih.gov/pubmed/32074281
http://dx.doi.org/10.1093/humrep/dez261

Ejemplares similares